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same subjects or different ones, with the advantage of potentially limiting
biological variability in the former case. Naturally, this is much easier to
achieve in animal studies rather than human, and problems are further
compounded by the fact of greater genetic variability in man compared to
inbred mouse strains. Unfortunately, to counter such limitations increased
sample numbers are often required to obtain signiﬁcant data from array
studies involving human tissue.
Microarrays are at their most powerful when used to address very well-
deﬁned research questions, for example, what is the effect of a speciﬁc
stimulus on a given cell type?; or, indeed in many plus/minus scenarios
(including knock-downs, knock-outs etc.). Another example along these
lines is the use of so-called RIP-Chip (immunoprecipiation of speciﬁc
proteins followed by array analysis) which is very useful when looking
at interactions between a single protein and many different RNA species.
In conclusion, array studies are most useful when applied to clearly de-
ﬁned research questions, and furthermore it is crucial to perform them
with utmost care both in experimental planning and execution to obtain
meaningful data. If such an approach is adopted array studies can be
extremely powerful as they can provide genuine new insights into many
pathophysiological processes.
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INTRARATICULAR THERAPIES IN THE MEDICAL MANAGEMENT OF OA
T. Conrozier
CENTRE Hosp. Lyon-Sud, Pierre Bénite, France
Osteoarthritis (OA) is the most common joint disease, with millions of
affected individuals worldwide. The prevalence of the disease is increasing
with age and consequently the affected population is chieﬂy constituted of
frail and elderly people. Given the chronic and non-life-threatening nature
of OA, a good safety proﬁle of treatments is essential.
Intra articular (IA) therapy gives the opportunity to reduce the risks of
adverse events compared to systemic treatments such as non steroidal anti
inﬂammatory drugs and cox2-inhibitors, particularly in patients with co-
morbidities (renal failure, arterial hypertension, gastrointestinal diseases).
Furthermore the direct administration of the drug into the OA joint allows
to expose the cartilage and synovial tissues to higher concentrations of the
drug compared to those obtained via systemic route.
The main risk associated with intraarticular administration is septic arthri-
tis but this risk is very small, when proper sterile technique is used,
including sterile syringes and skin antisepsis (0.002% from the experience
of 50,000 IA injections of corticosteroids). Proper needle placement within
the intra-articular cavity deserves careful attention. Even experienced se-
nior physicians fail to place the needle within the joint cavity in 20 to
50% of cases according to the joint and the approach. For deep joints such
as the hip, or small joints such as the trapezo-metacarpial joint, imaging
guidance using ultrasonography or ﬂuoroscopy is crucial. To limit the risk of
inaccurate needle placement, aspiration of synovial ﬂuid is recommended.
Synovial ﬂuid aspiration is indispensable when there is a joint effusion and
may contribute to the treatment response either via a direct effect or by
diminishing the volume available for drug dilution.
To date, three types of IA therapies are routinely available for decreas-
ing pain and/or improving function in patients with OA: glucocorticoids,
hyaluronic acid, and joint lavage.
Steroids IA injections are recommended in patients with joint effusion and
in those with signs of inﬂammation. The short-term beneﬁt (<4 weeks)
of IA corticosteroids (CS) in the treatment of knee OA is well established
with a size effect on pain of 0.58 (95%CI 0.34-0.87), and few side effects
have been reported such as temporary disturbance of diabetes and arterial
hypertension.
The response to hyaluronic acid (HA) products appears similar (ES pain
0.60/CI 0.37-0.83) but much more durable than that of CS (up to 26
weeks). No major safety issues were reported apart from some transient
local adverse events such as pain, swelling. Recent studies also suggest
a possible structure-modifying effect of HA injections. The key question
with HA treatment is to precisely deﬁne the type of patients likely to be
responders to treatment.
Joint lavage and arthroscopic debridement are often proposed in patients
unresponsive to CS and/or HA treatments, but there is no evidence of their
eﬃcacy (ES pain 0.21/-0.12-0.54).
New perspectives of IA therapy in OA include anti-cytokine therapy, gene
therapy, delivery of growth factors, stem cells therapy and new lubricant
agents.
The main goal of IA therapy for OA in the future will be to increase the
residence time of the drug within the joint in order to improve its diffusion
within the target tissues. In all cases the treatment must be individualized
for each patient in order to adapt it to the speciﬁcs of his condition.
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POST-TRAUMATIC OSTEOARTHRITIS REVISITED
S. Lohmander
Lund Univ., Lund, Sweden
OA is a multifactorial condition with genetic and environmental determi-
nants. All cases are inﬂuenced by both genetics and environment, with
the distribution and weight of causes forming a continuum between the
extremes of predominantly genetic or predominantly environmental. For
example, the risk of ‘post-traumatic OA’ after a meniscal injury of the knee
is inﬂuenced by a familial history of OA, by the presence of nodal OA of the
hand (marker of ‘generalized’ OA), by obesity, and by sex. The expression of
OA in any individual (presence or absence of inﬂammation, pain, cartilage
loss, bone formation, etc.) may further be determined by the particular mix
of genetic and environmental inﬂuences in that person.
OA where previous joint injury is identiﬁed as an important cause is
common, especially in younger persons. By 10-20 years after the rupture of
a cruciate ligament or meniscus of the knee, about half of those injured will
show radiographic signs of OA, and many will have signiﬁcant symptoms
already when aged 30 to 50. This represents an important clinical challenge
in that surgical resection or reconstruction of the torn meniscus or cruciate
ligament has not been proven to decrease the risk of OA development.
The young athlete with a knee injury leading to later OA may seem
straightforward to identify as post-traumatic OA, but the contribution
of additional risk factors as mentioned above should not be overlooked.
Moreover, the case deﬁnition is further muddled by the common presence
in middle-aged persons of incidental meniscus lesions associated with an
increased risk of knee OA development. Completing the continuum, lesions
of the menisci or cruciate ligament are frequent in OA knees, even in the
absence of a clear history of injury.
OA following joint injury offers unique opportunities for studying and
intervening in the earlier phases of human OA development. In parallel,
joint injury in the animal is a commonly used pre-clinical model for OA
development.
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ENDOCHONDRAL OSSIFICATION SIGNAL: A POTENTIAL THERAPEUTIC
TARGET FOR OSTEOARTHRITIS
H. Kawaguchi
Univ. of Tokyo, Tokyo, Japan
Osteoarthritis (OA) is characterized by cartilage degeneration and osteo-
phyte formation in joints. Despite its high prevalence and social needs for
the disease-modifying treatment, the molecular backgrounds underlying
the OA development are not fully clariﬁed. Considering that most of risk
factors approved so far are related to accumulated mechanical stress on
joint, elucidation of signals lying downstream of the mechanical stress
will disclose the molecular backgrounds. Using mouse experimental OA
models by producing instability in the knee joints surgically, proteinases
like matrix metalloproteinase-13 (MMP)13 and aggrecanase-2 (ADAMTS-5)
have been reported to be involved in the OA development. However,
clinical trials of the proteinase inhibitors have to date been unsuccessful
in terms of eﬃcacy and side effects, turning the interest of researchers to
other signals.
Our examination using the experimental mouse model conﬁrmed that
MMP13 was induced during the OA progression in the knee joint cartilage,
but more interestingly, type X collagen (COL10A1) that is characteristic
of hypertrophic differentiation of chondrocytes was strongly expressed
prior to the MMP13 induction. Chondrocyte hypertrophy with COL10A1
expression is known to initiate the endochondral ossiﬁcation process which
is not seen in the joint cartilage under physiological conditions, but is an
essential step for skeletal growth and fracture healing. The hypertrophic
chondrocytes then degrade cartilage matrix by proteinases to cause vas-
cularization by expressing VEGF for the recruitment of osteoprogenitor
cells.
To identify signals to induce endochondral ossiﬁcation and OA develop-
Abstracts from Invited Speakers / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S1–S8 S3
ment, we performed a screening of transcription factors using a promoter
assay of COL10A1 gene, and identiﬁed hypoxia-inducible factor 2α (HIF2A;
encoded by EPAS1) as the most potent transactivator. HIF2A enhanced
promoter activities of not only COL10A1, but also MMP13 and VEGF through
speciﬁc binding to the respective hypoxia-responsive elements. HIF2A,
independently of the oxygen-dependent hydroxylation, was essential for
endochondral ossiﬁcation of cultured chondrocytes and embryonic skeletal
growth in mice. HIF2A was induced in osteoarthritic cartilages of mice
and humans. The HIF2A heterozygous deﬁcient mice exhibited resistance
to OA development, and a functional SNP in the human HIF2A gene was
associated with knee OA in a Japanese population. Hence, HIF2A is an ex-
tensive transactivator during endochondral ossiﬁcation, and may represent
a therapeutic target for OA.
In addition to HIF2A, recent mouse genetic approaches by others and
us found that other endochondral ossiﬁcation signals like Runx2, C/EBPβ,
carminerin, osteoprotegerin, β-catenin, syndecan-4, hedgehog, etc. are in-
volved in the OA development. The proteinases produced during the
endochondral ossiﬁcation process are likely to cause cartilage degradation
at the center of the joint and osteophyte formation at the periphery.
The difference of the two sites may depend on the vascularity. At the
periphery, vascularity is accessible from the synovium or tendon, which
completes endochondral ossiﬁcation and forms osteophytes, just as it does
during skeletal growth and fracture healing. However, in the center, the
vascularity is not accessible from the edge, so that it may end up with
cartilage degradation without being replaced by bone. Molecules related
to the endochondral ossiﬁcation signals might become therapeutic targets
altering the course of this disabling disease.
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IMAGING IN OA: WHAT HAVEWE LEARNED ANDWHERE AREWE GOING?
F.W. Roemer1,2
1Klinikum Augsburg, Augsburg, Germany; 2Boston Univ. Sch. of Med., Boston,
MA
Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal dis-
ability with few conventional and surgical treatment options. Although
advanced imaging techniques are presently not applied in a clinical routine
setting for diagnostic purposes, rapid technical developments in mag-
netic resonance imaging (MRI) and application of image post-processing
methodology in combination with longitudinal studies applying MRI to
large cohorts have contributed greatly to disease understanding in recent
years. Focus of this presentation will be an overview of the role of MRI
A.) clinically including differential diagnosis and longitudinal monitoring of
disease on a patient level, B.) as a surrogate outcome measure for structural
endpoints in clinical studies, including efforts to isolate patients at greatest
risk for progression and C.) in understanding OA symptoms. In addition, the
current role of conventional radiography and other less commonly applied
methods will be re-discussed. As the vast majority of ongoing research in
OA imaging is focusing on the knee joint, the center of this overview will
also be the knee.
Methods: The radiographic examination of joints is still useful to establish
a diagnosis of OA and still holds an important role for deﬁning inclusion
criteria into clinical trials. Furthermore, radiographically detected joint
space narrowing is still the only accepted imaging outcome measure
in trials assessing disease modifying osteoarthritis drugs (DMOADs). The
current role of radiography will be discussed and advances in technology
of joint space width assessment will be presented.
The role of MRI has evolved rapidly over recent years. In the context
of joint imaging, cartilage imaging seems to be at the forefront of these
developments. Especially compositional MRI of cartilage ultrastructure has
lead to understanding of early, potentially reversible pathology. Advances
in quantitative morphologic cartilage assessment including novel ana-
lytic approaches have further added largely to understanding of disease
progression in recent years.
Due to MRI a change in paradigm has occurred in that it seems accepted
consensus now to perceive OA not as a disease of cartilage only but as
a whole-organ disorder involving multiple joint tissues leading eventually
to joint failure. Whole organ MRI assessment has contributed a lot to this
change in perception and will be discussed in detail. Many different joint
structures are of relevance in a clinical context and for disease progression.
Despite cartilage, most important seem to be the menisci, the subchondral
bone, ligamentous structures and the synovium. A consensus-based sugges-
tion for an MRI deﬁnition of early or pre-OA and deﬁnite OA is presented
in light of upcoming analyses of the large MRI datasets. Although MRI is
the most important methodology in imaging of OA and cartilage, other
modalities such as ultrasound, FDG-PET and computed tomography (CT)
do play a potentially important complimentary role that will be touched
brieﬂy.
Conclusions: The ﬁeld of imaging in OA and cartilage has evolved rapidly
and despite the continued lack of eﬃcient therapies there is hope that
especially imaging might be in a position to eventually drive therapeu-
tic break through. Publicly available OAI MRI data together with other
presently ongoing large epidemiological studies should allow the research
community to rapidly advance in understanding the natural course of the
disease and deﬁne risk factors relevant for OA disease progression. Current
data suggests that stratiﬁcation of risk is feasible to ascertain those at risk
for rapid progression using a number of different imaging-based metrics
including knee alignment, meniscal damage, bone marrow lesions, possibly
synovitis and joint effusion, and late stage disease. Identifying persons at
greatest risk for progression has important implications for clinical trial
planning and may possibly enhance study eﬃciency.
Eventually imaging and foremost MRI will be applied as surrogate measures
of disease progression, particularly in therapeutic intervention trials. Once
the clinical importance of these imaging endpoints is established, additional
advances in technology will drive a more comprehensive analysis of car-
tilage morphology, composition and other articular tissue pathology than
currently possible. This will be of particular importance once structure-
or disease-modifying interventions become available, as this will require
monitoring treatment response in large sets of OA patients. Only through
the availability of such interventions imaging will eventually play a relevant
and important role in clinical decision making and clinical practice.
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THE ROLE OF THE MENISCUS IN OSTEOARTHRITIS PATHOGENESIS
M. Englund
Lund Univ., Lund, Sweden
The menisci are two semi-circular ﬁbrocartilage structures positioned be-
tween the joint surfaces of the femur and tibia in the medial and lateral
knee joint compartments. Each meniscus covers approximately two-thirds
of the corresponding articular surface of the tibia. The menisci play a
critical protective role for the knee joint through shock absorption and load
distribution. When the knee is loaded, the tensile strength of the meniscal
matrix counteracts extrusion of the meniscus, and the meniscus distributes
stress over a large area of the articular cartilage; the healthy meniscus
mainly responds to load with compression. Loss of meniscal function by
meniscal tear or surgical removal of meniscal tissue has been strongly
associated with the development of radiographic knee osteoarthritis (OA).
Meniscal lesions have also been strongly linked to e.g. cartilage loss and
the development of subchondral bone marrow lesions which are both
prominent features of the disorder.
Meniscal lesions are regular ﬁndings on magnetic resonance imaging (MRI)
of the knee, especially in knees with OA typically in the form of horizontal,
ﬂap, and (or) complex tears, meniscal maceration, destruction or extru-
Figure 1. Prevalence of meniscal tear or maceration/destruction in the right knee among
991 middle-aged and elderly persons from the general population in Framingham, MA,
USA, according to age group and sex (all persons with previous knee surgery were ex-
cluded from the prevalence estimates of meniscal maceration/destruction) (Englund et
al. N Engl J Med. 2008 Sep 11;359[11]:1108-15).
